Who stays in medication treatment for opioid use disorder? A national study of outpatient specialty treatment settings

被引:69
|
作者
Krawczyk, Noa [1 ]
Williams, Arthur Robin [2 ]
Saloner, Brendan [3 ]
Cerda, Magdalena [1 ]
机构
[1] NYU, Grossman Sch Med, Dept Populat Hlth, Room 4-12,180 Madison Ave, New York, NY 10003 USA
[2] Columbia Univ, New York State Psychiat Inst, Dept Psychiat, New York, NY 10027 USA
[3] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA
关键词
Medication treatment; Opioid use disorder; Retention; Discontinuation; Overdose; METHADONE-MAINTENANCE TREATMENT; BUPRENORPHINE TREATMENT; UNITED-STATES; RETENTION; DISCONTINUATION; DEPENDENCE; OUTCOMES; RELEASE; PROGRAM; METAANALYSIS;
D O I
10.1016/j.jsat.2021.108329
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background: Maintenance treatments with medications for opioid use disorder (MOUD) are highly effective at reducing overdose risk while patients remain in care. However, few patients initiate medication and retention remains a critical challenge across settings. Much remains to be learned about individual and structural factors that influence successful retention, especially among populations dispensed MOUD in outpatient settings. Methods: We examined individual and structural characteristics associated with MOUD treatment retention among a national sample of adults seeking MOUD treatment in outpatient substance use treatment settings using the 2017 Treatment Episode Dataset-Discharges (TEDS-D). The study assessed predictors of retention in MOUD using multivariate logistic regression and accelerated time failure models. Results: Of 130,300 episodes of MOUD treatment in outpatient settings, 36% involved a duration of care greater than six months. The strongest risk factors for treatment discontinuation by six months included being of younger age, ages 18-29 ((OR):0.52 [95%CI:0.50-0.54]) or 30-39 (OR:0.57 [95%CI:0.55-0.59); experiencing homelessness (OR: 0.70 [95%CI:0.66-0.73]); co-using methamphetamine (OR:0.48 [95%CI:0.45-0.51]); and being referred to treatment by a criminal justice source (OR:0.55 [95%CI:0.52-0.59) or by a school, employer, or community source (OR:0.71 [95%CI:0.66-0.76). Conclusions: Improving retention in treatment is a pivotal stage in the OUD cascade of care and is critical to reducing overdose deaths. Efforts should prioritize interventions to improve retention among patients who are both prescribed and dispended MOUD, especially youth, people experiencing homelessness, polysubstance users, and people referred to care by the justice system who have especially short stays in care.
引用
下载
收藏
页数:11
相关论文
共 50 条
  • [41] Opioid use disorder treatment in rural settings: The primary care perspective
    Harder, Valerie S.
    Villanti, Andrea C.
    Heil, Sarah H.
    Smith, M. Lindsey
    Gaalema, Diann E.
    Meyer, Marjorie C.
    Schafrick, Nathaniel H.
    Sigmon, Stacey C.
    PREVENTIVE MEDICINE, 2021, 152
  • [42] Complexities with group therapy facilitation in substance use disorder specialty treatment settings
    Wendt, Dennis C.
    Gone, Joseph P.
    JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2018, 88 : 9 - 17
  • [43] News Media Reporting On Medication Treatment For Opioid Use Disorder Amid The Opioid Epidemic
    Kennedy-Hendricks, Alene
    Levin, Jonathan
    Stone, Elizabeth
    McGinty, Emma E.
    Gollust, Sarah E.
    Barry, Colleen L.
    HEALTH AFFAIRS, 2019, 38 (04) : 643 - 651
  • [44] Factors affecting medication assisted treatment success for opioid use disorder
    DeLellis, N.
    Mitchell, M.
    Frederick, A.
    Schachman, K.
    EUROPEAN JOURNAL OF PUBLIC HEALTH, 2020, 30
  • [45] Performance Measurement for Opioid Use Disorder Medication Treatment and Care Retention
    Williams, Arthur Robin
    Mauro, Christine M.
    Feng, Tianshu
    Wilson, Amanda
    Cruz, Angelo
    Olfson, Mark
    Crystal, Stephen
    Samples, Hillary
    Chiodo, Lisa
    AMERICAN JOURNAL OF PSYCHIATRY, 2023, 180 (06): : 454 - 457
  • [46] The role of NPs in medication-assisted treatment for opioid use disorder
    Cotton, Brandi Parker
    Ferszt, Ginette G.
    NURSE PRACTITIONER, 2018, 43 (05): : 8 - 8
  • [47] Polysubstance use before and during treatment with medication for opioid use disorder: Prevalence and association with treatment outcomes
    Bunting, Amanda M.
    Krawczyk, Noa
    Choo, Tse-Hwei
    Pavlicova, Martina
    McNeely, Jennifer
    Tofighi, Babak
    Rotrosen, John
    Nunes, Edward
    Lee, Joshua D.
    JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2022, 143
  • [48] Injectable opioid agonist treatment for opioid use disorder: a national clinical guideline
    Fairbairn, Nadia
    Ross, Josey
    Trew, Michael
    Meador, Karine
    Turnbull, Jeff
    MacDonald, Scott
    Oviedo-Joekes, Eugenia
    Le Foll, Bernard
    Goyer, Marie-Eve
    Perreault, Michel
    Sutherland, Christy
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2019, 191 (38) : E1049 - E1056
  • [49] Mindfulness-Based Relapse Prevention with Individuals Receiving Medication-Assisted Outpatient Treatment for Opioid Use Disorder
    Zullig, Keith J.
    Lander, Laura R.
    Sloan, Samantha
    Brumage, Michael R.
    Hobbs, Gerry R.
    Faulkenberry, Laurel
    MINDFULNESS, 2018, 9 (02) : 423 - 429
  • [50] Mindfulness-Based Relapse Prevention with Individuals Receiving Medication-Assisted Outpatient Treatment for Opioid Use Disorder
    Keith J. Zullig
    Laura R. Lander
    Samantha Sloan
    Michael R. Brumage
    Gerry R. Hobbs
    Laurel Faulkenberry
    Mindfulness, 2018, 9 : 423 - 429